Loading…
RPK Pharmaceuticals Inc. was cited for failure to comply with drug listing requirements and misbranding of their clotrimazole and betamethasone dipropionate cream product (NDC 53002-9740). The company submitted a label image stating "triamcinolone 0.1% ointment" to FDA's Drug Registration and Listing System, which did not match the actual drug product listed—representing a violation of Section 510(j) of the Federal Food, Drug, and Cosmetic Act. This compliance failure followed two prior FDA notices issued in April and May 2020 regarding the same listing deficiency, which ultimately resulted in the product's removal from FDA's Online NDC Directory.